Center for Manufacturing Innovation, Fraunhofer USA, Brookline, Massachusetts 02446, USA.
Lab Chip. 2012 Nov 7;12(21):4523-32. doi: 10.1039/c2lc40531h.
The emergence and spread of bacterial resistance to ever increasing classes of antibiotics intensifies the need for fast phenotype-based clinical tests for determining antibiotic susceptibility. Standard susceptibility testing relies on the passive observation of bacterial growth inhibition in the presence of antibiotics. In this paper, we present a novel microfluidic platform for antibiotic susceptibility testing based on stress-activation of biosynthetic pathways that are the primary targets of antibiotics. We chose Staphylococcus aureus (S. aureus) as a model system due to its clinical importance, and we selected bacterial cell wall biosynthesis as the primary target of both stress and antibiotic. Enzymatic and mechanical stresses were used to damage the bacterial cell wall, and a β-lactam antibiotic interfered with the repair process, resulting in rapid cell death of strains that harbor no resistance mechanism. In contrast, resistant bacteria remained viable under the assay conditions. Bacteria, covalently-bound to the bottom of the microfluidic channel, were subjected to mechanical shear stress created by flowing culture media through the microfluidic channel and to enzymatic stress with sub-inhibitory concentrations of the bactericidal agent lysostaphin. Bacterial cell death was monitored via fluorescence using the Sytox Green dead cell stain, and rates of killing were measured for the bacterial samples in the presence and absence of oxacillin. Using model susceptible (Sanger 476) and resistant (MW2) S. aureus strains, a metric was established to separate susceptible and resistant staphylococci based on normalized fluorescence values after 60 min of exposure to stress and antibiotic. Because this ground-breaking approach is not based on standard methodology, it circumvents the need for minimum inhibitory concentration (MIC) measurements and long wait times. We demonstrate the successful development of a rapid microfluidic-based and stress-activated antibiotic susceptibility test by correctly designating the phenotypes of 16 additional clinically relevant S. aureus strains in a blinded study. In addition to future clinical utility, this method has great potential for studying the effects of various stresses on bacteria and their antibiotic susceptibility.
细菌对抗生素的耐药性不断增强,这加剧了对快速基于表型的临床抗生素药敏试验的需求。标准药敏试验依赖于在抗生素存在的情况下被动观察细菌生长抑制。在本文中,我们提出了一种基于抗生素作用靶点的生物合成途径的应激激活的新型微流控药敏测试平台。我们选择金黄色葡萄球菌(S. aureus)作为模型系统,因为它具有临床重要性,并且我们选择细菌细胞壁生物合成作为应激和抗生素的主要靶点。酶和机械应激用于破坏细菌细胞壁,而β-内酰胺类抗生素干扰修复过程,导致没有耐药机制的菌株迅速死亡。相比之下,耐药菌在检测条件下仍然存活。将细菌共价结合到微流控通道的底部,然后通过微流控通道中的培养液流动产生机械剪切应力,并通过亚抑菌浓度的杀菌剂溶葡萄球菌酶产生酶应激。通过使用 Sytox Green 死细胞染色剂进行荧光监测来监测细菌死亡,并且在存在和不存在苯唑西林的情况下测量细菌样品的杀伤率。使用模型敏感(Sanger 476)和耐药(MW2)金黄色葡萄球菌菌株,建立了一种基于暴露于应激和抗生素 60 分钟后的归一化荧光值来分离敏感和耐药葡萄球菌的度量标准。由于这种开创性的方法不是基于标准方法,因此它避免了需要最小抑菌浓度(MIC)测量和长时间等待。我们通过在盲法研究中正确指定另外 16 种临床相关金黄色葡萄球菌菌株的表型,成功地开发了一种快速基于微流控和应激激活的抗生素药敏试验。除了未来的临床应用外,该方法还有很大的潜力用于研究各种应激对细菌及其抗生素敏感性的影响。